Base de dados : LILACS
Pesquisa : D08.811.277.656.074.500.340 [Categoria DeCS]
Referências encontradas : 25 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 25 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Brigido, Luís Fernando de Macedo
Teixeira, Jorge Juarez Vieira
Bertolini, Dennis Armando
Texto completo
Id: lil-643952
Autor: Gaspareto, Karine Vieira; Mello, Flávia Myrian Martins de Almeida; Dias, José Ricardo Colleti; Meneguetti, Vera Alice Fernandes; Storti, Marta Evelyn Giansante; Ferreira, João Leandro de Paula; Lança, André Minhoto; Rodrigues, Rosângela; Brígido, Luis Fernando de Macedo; Teixeira, Jorge Juarez Vieira; Bertolini, Dennis Armando.
Título: Genetic diversity and primary resistance among HIV-1-positive patients from Maringá, Paraná, Brazil / Diversidade genética e resistência primária entre pacientes HIV-1-positivos de Maringá, Paraná, Brasil
Fonte: Rev. Inst. Med. Trop. Säo Paulo;54(4):207-213, July-Aug. 2012. ilus, graf, tab.
Idioma: en.
Resumo: The objective of this study is to identify subtypes of Human Immunodeficiency Virus type 1 (HIV-1) and to analyze the presence of mutations associated to antiretroviral resistance in the protease (PR) and reverse transcriptase (RT) regions from 48 HIV-1 positive treatment naïve patients from an outpatient clinic in Maringá, Paraná, Brazil. Sequencing was conducted using PR, partial RT and group-specific antigen gene (gag) nested PCR products from retrotranscribed RNA. Transmitted resistance was determined according to the Surveillance Drug Resistance Mutation List (SDRM) algorithm. Phylogenetic and SimPlot analysis of concatenated genetic segments classified sequences as subtype B 19/48 (39.6%), subtype C 12/48 (25%), subtype F 4/48 (8.3%), with 13/48 (27.1%) recombinant forms. Most recombinant forms were B mosaics (B/F 12.5%, B/C 10.4%), with one C/F (2.1%) and one complex B/C/F mosaic (2.1%). Low levels of transmitted resistance were found in this study, 2/48 (2.1% to NRTIs and 2.1% for PI). This preliminary data may subsidize the monitoring of the HIV evolution in the region.

O objetivo foi identificar subtipos do Vírus da Imunodeficiência Humana tipo-1 (HIV-1) e analisar a presença de mutações/polimorfismos nas regiões da protease (PR) e transcriptase reversa (TR) de 48 pacientes virgens de tratamento atendidos no município de Maringá, Paraná, Brasil. O sequenciamento foi conduzido usando produtos de nested PCR dos genes da PR, TR parcial e group-specific antigen gene (gag) de RNA retrotranscrito. A interpretação da resistência transmitida foi realizada segundo o algoritmo Surveillance Drug Resistance Mutation List (SDRM). As análises filogenética e SimPlot dos segmentos concatenados classificaram as sequências como subtipo B 19/48 (39,6%), subtipo C 12/48 (25%), subtipo F 4/48 (8,3%), com 13/48 (27,1%) formas recombinantes. A maioria das formas recombinantes era mosaicos B (B/F 12,5%, B/C 10,4%), com um C/F (2,1%) e um mosaico complexo B/C/F (2,1%). A prevalência de resistência transmitida foi de 4,2% (2,1% para ITRN e 2,1% para IP). Baixos níveis de resistência transmitida foram encontrados nesse estudo, 2/48 (2,1% para INTR e 2,1% para IP). Esses achados, embora preliminares, podem contribuir no monitoramento da epidemia de HIV na região.
Descritores: Farmacorresistência Viral/genética
Infecções por HIV/virologia
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
Mutação/genética
-Sequência de Bases
CDABBREVIATIONS AS TOPIC-CDABDOMINAL NEOPLASMS RATIO
Genótipo
HIV-1
Dados de Sequência Molecular
Filogenia
Limites: Adolescente
Adulto
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Adulto Jovem
Responsável: BR1.1 - BIREME


  2 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Brito, Ana Maria de
Texto completo
Id: lil-626436
Autor: Cavalcanti, Ana Maria Salustiano; Brito, Ana Maria de; Salustiano, Daniela Medeiros; Lima, Kledoaldo Oliveira de; Silva, Sirleide Pereira da; Diaz, Ricardo Sobhie; Lacerda, Heloisa Ramos.
Título: Primary resistance of HIV to antiretrovirals among individuals recently diagnosed at voluntary counselling and testing centres in the metropolitan region of Recife, Pernambuco
Fonte: Mem. Inst. Oswaldo Cruz;107(4):450-457, June 2012.
Idioma: en.
Resumo: Determining the prevalence and type of antiretroviral (ARV) resistance among ARV-naïve individuals is important to assess the potential responses of these individuals to first-line regimens. The prevalence of primary resistance and the occurrence of recent infections among individuals with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) were identified among recently diagnosed patients at five sexually transmitted disease/AIDS testing and counselling centres in the metropolitan region of Recife (RMR), Pernambuco, Brazil, between 2007-2009. One-hundred and eight samples were analysed using the Calypte® BED assay. Males predominated (56%), as did patients aged 31-50 years. Twenty-three percent presented evidence of a recent HIV infection. The median CD4+ T lymphocyte count was 408 cells/mm³ and the median viral load was 3.683 copies/mL. The prevalence of primary resistance was 4.6% (confidence interval 95% = 1-8.2%) based on criteria that excluded common polymorphisms in accordance with the surveillance drug resistance mutation criteria. The prevalence of resistance to non-nucleoside reverse transcriptase, nucleoside/nucleotide reverse transcriptase and protease inhibitors were 3.8%, 1.5% and 0.8%, respectively. Fifty-seven percent of strains were from clade B, 37.7% were clade F and 3.1% were clade C; there were no statistically significant differences with respect to resistance between clades. Recent infection tended to be more common in men (p = 0.06) and in municipalities in the south of the RMR (Jaboatão dos Guararapes and Cabo de Santo Agostinho) (p = 0.046). The high prevalence of recent infection and the high prevalence of non-B strains in this poor Brazilian region merit further attention.
Descritores: Farmacorresistência Viral/genética
Infecções por HIV/virologia
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
Mutação/genética
-Fármacos Anti-HIV/uso terapêutico
CDABBREVIATIONS AS TOPIC LYMPHOCYTE COUNT
Genótipo
Infecções por HIV/tratamento farmacológico
Infecções por HIV/epidemiologia
HIV-1
Prevalência
Inibidores de Proteases/uso terapêutico
RNA Viral/genética
Inibidores da Transcriptase Reversa/uso terapêutico
Fatores Socioeconômicos
População Urbana
Carga Viral
Limites: Adulto
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  3 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Saúde Pública
Texto completo
Id: lil-612968
Autor: Castillo, Juan; Arteaga, Griselda; Mendoza, Yaxelis; Martínez, Alexander A; Samaniego, Rigoberto; Estripeaut, Dora; Page, Kathleen R; Smith, Rebecca E; Sosa, Nestor; Pascale, Juan M.
Título: HIV transmitted drug resistance in adult and pediatric populations in Panama / Farmacorresistencia transmitida del VIH en poblaciones adultas y pediátricas en Panamá
Fonte: Rev. panam. salud pública = Pan am. j. public health;30(6), Dec. 2011. tab.
Idioma: en.
Resumo: Objetivo. Investigar la prevalencia de farmacorresistencia transmitida del VIH en adultos en Panamá mediante un estudio del umbral modificado de la Organización Mundial de la Salud (OMS) e investigar las tasas de resistencia inicial en lactantesseropositivos para el VIH en Panamá.Métodos. En el Instituto Conmemorativo Gorgas, en 47 adultos seropositivos al VIH se efectuó la genotipificación de las mutaciones asociadas con la farmacorresistencia transmitida en los genes de la transcriptasa inversa y la proteasa del VIH-1, según las directrices del estudio umbral de la OMS, modificadas para incluir a las personas ≤ 26 años de edad. Las tasas de prevalencia de las mutaciones farmacorresistentes contra tres clases de fármacos antirretroviral —inhibidores de la transcriptasa inversaanálogos de nucleósidos, inhibidores de la transcriptasa inversa no análogos de nucleósidos e inhibidores de la proteasa— se clasificaron en bajas (< 5,0%), moderadas (5,0%–15,0%) o altas (> 15,0%). También se llevó a cabo genotipificación y se calcularonlas tasas de prevalencia de las mutaciones causantes de farmacorresistencia en 25 lactantes.Resultados. En los adultos de Panamá la farmacorresistencia transmitida fue moderada: 6 de 47 adultos seropositivos para el VIH presentaron una o más mutacionesasociadas con farmacorresistencia transmitida. Las mutaciones farmacorresitentes de transmisión horizontal fueron moderadas para los inhibidores de la transcriptasainversa análogos de nucleósidos y los inhibidores de la transcriptasa inversa no análogos de nucleósidos, y bajas para los inhibidores de la proteasa. En Panamá la transmisiónvertical del VIH ha disminuido en el período 2002–2007, pero la prevalenciade la farmacorresistencia del VIH transmitida por vía vertical es moderada (12,0%) y está surgiendo como un problema debido a la cobertura antirretroviral incompletadurante el embarazo...

Objective. To investigate the prevalence of transmitted drug-resistant HIV among adults in Panama by using a modified World Health Organization Threshold Survey (WHO-TS) and to investigate rates of initial resistance among HIV-positive infants in Panama.Methods. At the Gorgas Memorial Institute, 47 HIV-positive adults were genotyped for mutations associated with transmitted drug resistance (TDR) in the reverse transcriptase andprotease genes of HIV-1, according to WHO-TS guidelines, modified to include patients ≤ 26 years old. Prevalence rates for drug-resistance mutations against three classes of antiretroviraldrugs—nucleoside analog reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors—were calculated as low (< 5.0%), moderate (5.0%–15.0%), and high (> 15.0%). Twenty-five infant patients were also genotyped and prevalence rates for drug-resistance mutations were calculated. Results. TDR among Panamanian adults was moderate: 6 of 47 HIV-positive adultsshowed one or more mutations associated with TDR. Horizontal TDR mutations were moderate for NRTIs and NNRTIs and low for protease inhibitors. Vertical transmission of HIV inPanama has decreased for 2002–2007, but vertical HIV TDR prevalence is moderate (12.0%) and is emerging as a problem due to incomplete antiretroviral coverage in pregnancy. Conclusions. The prevalence of HIV TDR indicated by this study, combined with knownrates of HIV infection in Panama, suggests more extensive surveys are needed to identify risk factors associated with transmission of HIV drug resistance. Specific WHO-TS guidelines for monitoring vertical transmission of drug-resistant HIV should be established.
Descritores: Fármacos Anti-HIV/farmacologia
Farmacorresistência Viral
HIV-1
-Fármacos Anti-HIV/uso terapêutico
Farmacorresistência Viral/genética
Genes pol
Genótipo
Infecções por HIV/tratamento farmacológico
Infecções por HIV/epidemiologia
Infecções por HIV/transmissão
Infecções por HIV/virologia
Inibidores da Protease de HIV/farmacologia
Inibidores da Protease de HIV/uso terapêutico
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
Transmissão Vertical de Doença Infecciosa
Prevalência
Panamá/epidemiologia
Complicações Infecciosas na Gravidez/virologia
Inibidores da Transcriptase Reversa/farmacologia
Inibidores da Transcriptase Reversa/uso terapêutico
Limites: Adolescente
Adulto
Feminino
Humanos
Lactente
Recém-Nascido
Masculino
Gravidez
Adulto Jovem
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  4 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-604034
Autor: Melo, Nadja Rodrigues de.
Título: Caracterização de leveduras de cavidade oral de crianças infectadas pelo HIV-1, antes e durante o uso de inibidor de protease / Characterization of candida oral flora in HIV-1 infected children in the HAART era.
Fonte: Campinas; s.n; 2006. 184 p. tab, graf.
Idioma: pt.
Tese: Apresentada a Universidade Estadual de Campinas. Faculdade de Ciências Médicas para obtenção do grau de Doutor.
Resumo: O presente estudo caracterizou a flora oral de Candida em 52 crianças infectadas pelo HIV-1 em dois períodos, definidos como período I antes da introdução de inibidores de protease no esquema de terapia antiretroviral para HIV-1 e período II após a introdução de inibidores de protease. Comparou-se as espécies de Candida identificadas nos períodos I e II. Isolados do períodos I foram identificados e as crianças em sua maioria (80 por cento) estavam colonizadas por C. albicans. Redução no percentual de colonização por C. albicans de 80 por cento para 52 por cento, nos períodos I e II respectivamente, sugere mudança na colonização oral por Candida após a introdução da terapêutica com inibidores de protease HIV (IP). Destaca-se particularmente o aumento da incidência de isolados Não?albicans (p=0.005) no período II. No período I haviam 8 crianças que estavam colonizadas por espécies Não-albicans e no período II haviam 20 crianças colonizadas com isolados Não-albicans. Investigou-se a prevalência de C. dubliniensis na família de uma das crianças que estava colonizada por esta levedura. Do total de 52 crianças 38.4 por cento mostraram manifestação oral associada a colonização por Candida. Observou-se alta sensibilidade dos isolados aos agentes antifúngicos testados, mas 4 por cento dos isolados exibiram resistência ao fluconazol. Documentou...

This study characterized the Candida oral flora from 52 Brazilian HIV 1-infected children, comparing the Candida species identified in two periods before (PI) and under (PII) the introduction of the HIV Protease Inhibitor therapy. The majority (80 percent) of the children from the PI group were colonized by C. albicans. Children in the PII (52 percent) were colonized by C. albicans and 28 percent of them carried on mixed colonization (C. albicans and Non?albicans isolates). Therefore when we compared the periods I and II, after the inhibitor protease usage there was an important decrease in the percentile of colonization for C. albicans of 80 porcent to 52 percent, suggesting an important change of the Candida oral colonization after the HIV protease inhibitors introduction. Particularly with increase of the Non-albicans isolates incidence (p=0.005) in the period II. In PI there were 8 children that were colonized by Non-albicans species and in the PII there were 20 children colonized with Non?albicans isolates. Rare Candida species were identified, particularly we investigated the C. dubliniensis prevalence in a HIV-infected child?s family. Of 52 children in this study 20 (38.4 percent) of them showed oral lesions associated to the Candida colonization. In spite of the high susceptibility of the isolates to the antifungal agents tested in this study, 4.4 percent (n=2) exhibited resistance...
Descritores: Terapia Antirretroviral de Alta Atividade
Candida albicans
Infecções por HIV
HIV-1
-Candida
Protease de HIV
Limites: Humanos
Criança
Responsável: BR734.1 - Biblioteca Central Cesar Lattes - BCCL
BR734.1; T/UNICAMP, M491c


  5 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Id: lil-598197
Autor: Hazuda, Daria J.
Título: Resistencia a los inhibidores de la integración del Virus de la Inmunodeficiencia Humana Tipo I: [revisión] / Resistance to inhibitors of the Human Immunodeficiency Virus Type I integration: [review]
Fonte: Actual. SIDA;18(70):135-141, nov. 2010. ilus.
Idioma: es.
Resumo: En esta revisión, se resume el rol de la integrasa en la infección por VIH-1, el mecanismo de los inhibidores de la integrasa y la resistencia, con énfasis en el Raltegravir (RAL), el primer inhibidor de la integrasa autorizado para tratar la infección por VIH-1.

This review will summarize the role of integrase in HIV-1 infection, the mechanism of integrase inhibitors and resistance with an emphasis on Raltegravir (RAL), the first integrase inhibitor licensed to treat HIV-1 infection.
Descritores: Antirretrovirais
Protease de HIV
HIV-1
Inibidores de Integrase/farmacologia
Inibidores da Transcriptase Reversa
Limites: Humanos
Tipo de Publ: Revisão
Responsável: AR392.1 - Biblioteca


  6 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-593370
Autor: Grotto, Rejane Maria Tommasini; Corvino, Sílvia Maria; Munhoz, Lilian da Silva Reis; Ghedini, Cibele Gomes; Pardini, Maria Inês de Moura Campos.
Título: A first case of protease codon 35 amino acid insertion in a HIV-1 subtype B sequence detected in the Bauru region, state of São Paulo, Brazil: case report / Primeiro caso de inserção de aminoácidos no codon 35 da protease em uma sequência de HIV-1 do subtipo B detectada na região de Bauru, estado de São Paulo, Brasil: relato de caso
Fonte: Rev. Soc. Bras. Med. Trop;44(3):392-394, May-June 2011. ilus, tab.
Idioma: en.
Resumo: Amino acid insertions in the protease have rarely been described in HIVinfected patients. One of these insertions has recently been described in codon 35, although its impact on resistance remains unknown. This study presents a case of an HIV variant with an insertion in codon 35 of the protease, described for the first time in Bauru, State of Sao Paulo, Brazil, circulating in a 38-year-old caucasian male with asymptomatic HIV infection since 1997. The variant isolated showed a codon 35 insertion of two amino acids in the protease: a threonine and an aspartic acid, resulting in the amino acid sequence E35E_TD.

Inserções de aminoácidos na protease têm sido raramente descritas em pacientes infectados pelo HIV. Uma destas inserções foi, recentemente, descrita no codon 35, embora seu impacto na resistência mantém-se pouco conhecido. Este trabalho apresenta um caso de uma variante viral com inserção no codon 35 da protease, descrita pela primeira vez em Bauru, São Paulo, Brasil, circulante em um homem, caucasiano, com 38 anos, o qual apresenta infecção assintomática pelo HIV desde 1997. A variante isolada mostrou uma inserção no codon 35 da protease de dois aminoácidos: uma treonina e um ácido aspártico, resultando na sequência de aminoácidos E35E_TD.
Descritores: Códon/genética
Infecções por HIV/virologia
Protease de HIV/genética
HIV-1
Mutagênese Insercional/genética
-Sequência de Aminoácidos
Brasil
Dados de Sequência Molecular
Limites: Adulto
Humanos
Masculino
Tipo de Publ: Relatos de Casos
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  7 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-561208
Autor: Toledo, Paula Virginia Michelon; Carvalho, Denise Siqueira de; Romagnoli, Luiza; Marcinko, Gustavo; Cunha, Clovis Arns da; Souza, Margely Nunes de; Brindeiro, Rodrigo; Queiroz-Telles, Flávio de.
Título: HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil
Fonte: Braz. j. infect. dis;14(4):360-371, July-Aug. 2010. ilus, tab.
Idioma: en.
Resumo: Antiretroviral therapy (ART) has reduced morbidity and mortality related to human immunodeficiency virus (HIV) infection, but in spite of this advance, HIV mutations decrease antiretroviral susceptibility, thus contributing to treatment failure in patients. Genotyping HIV-1 allows the selection of new drugs after initial drug failure. This study evaluated the genotypic profile of HIV-1 isolates from treated (drug-experienced) patients in Paraná, Brazil. The prevalence of mutations in reverse transcriptase (RT) and protease (PR) genes were assessed. We analyzed 467 genotypes of patients with HIV-1 viral loads above 1,000 copies/mL. Mutations at HIV-1 RT and PR genes and previously used ART regimens were recorded. The most prevalent RT mutations were: 184V (68.31 percent), 215YF (51.6 percent), 103NS (46 percent), 41L (39.4 percent), 67N (38.54 percent), 210W (23.5 percent), 190ASE (23.2 percent), and 181C (17.4 percent). PR mutations were 90M (33.33 percent), 82ATFS (29 percent), 46I (26.8 percent) and 54V (22.2 percent). The prevalence of mutations was in line with previous national and international reports, except to nonnucleoside analogue reverse transcriptase inhibitors related mutations, which were more prevalent in this study. Previous exposure to antiretroviral drugs was associated with genotypic resistance to specific drugs, leading to treatment failure in HIV patients.
Descritores: Fármacos Anti-HIV/uso terapêutico
Infecções por HIV/tratamento farmacológico
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
Mutação/genética
-Terapia Antirretroviral de Alta Atividade
Brasil
Farmacorresistência Viral/genética
Genótipo
Infecções por HIV/virologia
HIV-1
Falha de Tratamento
Carga Viral
Limites: Adulto
Feminino
Humanos
Masculino
Responsável: BR1.1 - BIREME


  8 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-556834
Autor: Toledo, Paula Virginia Michelon; Carvalho, Denise Siqueira de; Rossi, Silvia Gomes de; Brindeiro, Rodrigo; Queiroz-Telles, Flávio de.
Título: Genetic diversity of human immunodeficiency virus-1 isolates in Paraná, Brazil
Fonte: Braz. j. infect. dis;14(3):230-236, May-June 2010. ilus, tab.
Idioma: en.
Resumo: OBJECTIVE: Because epidemiological data on circulating HIV subtypes among HIV-positive patients in the state of Paraná were not known until now, the aims of this study were to describe the genetic diversity profile of HIV-1 in treated patients in Paraná, Brazil, and report the differences in protease (PR) and reverse transcriptase (RT) mutations in HIV-1 subtypes. PATIENTS AND METHODS: A cross-sectional study was conducted from 2003 to 2006. Plasma viral RNA of 389 patients was extracted and PR and RT genes were polymerase chain reaction-amplified and sequenced. Sequences were subtyped and examined for antiretroviral resistance mutations. Data on gender of patient harboring the viruses and past history of antiretroviral treatment were also collected. RESULTS: Most viruses were either subtype B (61.44 percent) or subtype C (20.57 percent). Subtype C and F were more frequent in women (p < 0.00). The prevalence of subtypes was similar over the years studied. The most frequent RT mutations in all subtypes were M184V and mutations at codons 215, 41, 103, 67, 219, and 190. Mutations 41L, 210W, 215YF, and 74V were significantly more prevalent on subtype B, and the mutation 106M was significantly more prevalent on subtype C. The most frequent major PI mutations in all subtypes occurred at codons 46, 82, and 90. PR mutations 32I, 46I, and 84V were significantly more prevalent on subtype B. The minor PI mutations on codons 36, 93, and 63 were more prevalent on subtypes F, C, and B, respectively. CONCLUSION: We concluded that the predominant strain of HIV-1 in Paraná is subtype B, followed by subtype C. Some mutations at PR and TR had subtype predominance in accordance with other authors' report.
Descritores: Farmacorresistência Viral/genética
Variação Genética/genética
Infecções por HIV/virologia
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
Mutação/genética
-Terapia Antirretroviral de Alta Atividade
Estudos Transversais
Genótipo
Infecções por HIV/tratamento farmacológico
HIV-1
Reação em Cadeia da Polimerase
RNA Viral/genética
Limites: Adulto
Feminino
Humanos
Masculino
Responsável: BR1.1 - BIREME


  9 / 25 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-505350
Autor: Varella, Rafael Brandão; Ferreira, Selma Baía; Castro, Márcia Braga de; Tavares, Marisa Dias; Zalis, Mariano Gustavo.
Título: Prevalence of resistance-associated mutations in Human Immunodeficiency Virus type 1-positive individuals failing HAART in Rio de Janeiro, Brazil
Fonte: Braz. j. infect. dis;12(5):380-384, Oct. 2008. tab.
Idioma: en.
Resumo: We investigated the occurrence of HIV-1 antiretroviral resistance in individuals failing to respond to highly active antiretroviral therapy (HAART) attended by RENAGENO from 2001-2004. One hundred and seventeen patients were selected for this study; their plasma viral RNA was extracted and the PR and RT genes sequenced to examine subtype, genetic polymorphisms and mutations associated with resistance to antiretroviral drugs. HIV-1 sequence analysis showed that 86/100 (86 percent) were infected with subtype B, 7/100 (7 percent) with subtype F and 7/100 (7 percent) with RT/PR hybrid forms (2 D/B, 2 F/B, 2 B/F and 1 D/F). In 14 (12 percent) of the samples, the subtype was not determined. The prevalence of resistance mutations was high (93.1 percent), mainly in the RT gene. The most prevalent resistance mutations were: M184V (60.7 percent), T215Y (49.6 percent) and M41L (46.7 percent) in the RT gene and L90M (19.6 percent), M46I (16.2 percent) and D30N (12.8 percent) in the PR gene. The frequency of resistance mutations tended to increase from the first to the second therapeutic scheme failure (p=0.079); but it stabilized after subsequent failures (p=0.875). Our finding of a high frequency of drug resistant HIV-1 samples supports the need for continuous genotypic monitoring of patients failing HAART.
Descritores: Terapia Antirretroviral de Alta Atividade
Farmacorresistência Viral/genética
Infecções por HIV/virologia
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
HIV-1
-Brasil
Genótipo
Infecções por HIV/tratamento farmacológico
HIV-1
Mutação/genética
Polimorfismo Genético
RNA Viral/genética
Falha de Tratamento
Carga Viral
Limites: Adulto
Feminino
Humanos
Masculino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME


  10 / 25 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Chile
Texto completo
Id: lil-472853
Autor: Acevedo, William; Gallardo, Ana Marfa; Galaz, José; Afani, Alejandro; Cortés, Esteban.
Título: Detección de resistencia primaria en pacientes chilenos infectados por VIH / Detection of primary antiretroviral resistance in Chilean patients recently infected with human immunodeficiency virus (HIV)
Fonte: Rev. méd. Chile;135(11):1406-1413, nov. 2007. mapas, tab.
Idioma: es.
Resumo: Background: In countries with universal access to antiretroviral therapy a progressive increase in the number of patients that are infected with resistant virus, is observed. Aim To detect the presence of primary resistance to antiretroviral drugs among patients with a recent diagnosis of HIV infection. Material and methods: Twenty five male patients aged 25 to 45 years, with a diagnosis of a recent HIV infection, done between 2004 and 2005, were studied. Genotypic resistance to antiretroviral drugs was studied using the Genetic Resistance Test TRUGENE® from Bayer. Results: Resistance mutations were detected in 10 patients. All had an university title or had university studies. All lived in northeastern Santiago and had risky sexual behaviors while traveling abroad. Seven mutations were detected in reverse transcriptase. Of these, three were associated to a high resistance level and four, to an intermediate or low resistance, were also detected. Conclusions: A high frequency of genotypic resistance was detected in this group of Chilean patients recently infected with HIV. A higher socioeconomic status and lifestyle could have influenced these results.
Descritores: Fármacos Anti-HIV/farmacologia
Farmacorresistência Viral/genética
HIV
Infecções por HIV/virologia
Mutação/genética
-Fármacos Anti-HIV/uso terapêutico
Chile
Genótipo
HIV
Infecções por HIV/tratamento farmacológico
Protease de HIV/genética
Transcriptase Reversa do HIV/genética
Carga Viral
Limites: Adulto
Humanos
Masculino
Pessoa de Meia-Idade
Responsável: BR1.1 - BIREME



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde